$19.51
0.76% day before yesterday
Nasdaq, Dec 27, 10:00 pm CET
ISIN
GB00BY2Z0H74
Symbol
PRTC
Sector
Industry

PureTech Health Plc - ADR Stock price

$19.51
-3.88 16.59% 1M
-4.99 20.37% 6M
-8.67 30.77% YTD
-4.15 17.54% 1Y
-18.39 48.52% 3Y
-18.99 49.32% 5Y
-18.99 49.32% 10Y
Nasdaq, Closing price Fri, Dec 27 2024
-0.15 0.76%
ISIN
GB00BY2Z0H74
Symbol
PRTC
Sector
Industry

Key metrics

Market capitalization $467.11m
Enterprise Value $241.25m
P/E (TTM) P/E ratio negative
EV/FCF (TTM) EV/FCF negative
EV/Sales (TTM) EV/Sales 513.30
P/S ratio (TTM) P/S ratio 993.85
P/B ratio (TTM) P/B ratio 1.48
Revenue growth (TTM) Revenue growth -96.16%
Revenue (TTM) Revenue $470.00k
EBIT (operating result TTM) EBIT $-135.88m
Free Cash Flow (TTM) Free Cash Flow $-119.96m
EPS (TTM) EPS $-3.02
P/E forward negative
P/S forward 26.10
EV/Sales forward 13.48
Short interest 0.05%
Show more

Is PureTech Health Plc - ADR a Top Scorer Stock based on the Dividend, High-Growth-Investing or Leverman Strategy?

As a Free StocksGuide user, you can view scores for all 6,886 stocks worldwide.

PureTech Health Plc - ADR Stock Analysis

Unlock Scores for Free

Analyst Opinions

3 Analysts have issued a PureTech Health Plc - ADR forecast:

3x Buy
100%

Analyst Opinions

3 Analysts have issued a PureTech Health Plc - ADR forecast:

Buy
100%

Financial data from PureTech Health Plc - ADR

Income Statement P&L | Balance Sheet | Cash Flow


TTM Annually
Jun '24
+/-
%
0.47 0.47
96% 96%
100%
- Direct Costs 3.67 3.67
-
781%
-3.20 -3.20
-
-681%
- Selling and Administrative Expenses 47 47
5% 5%
10,070%
- Research and Development Expense 82 82
34% 34%
17,377%
-132 -132
22% 22%
-28,130%
- Depreciation and Amortization 3.67 3.67
53% 53%
781%
EBIT (Operating Income) EBIT -136 -136
23% 23%
-28,911%
Net Profit -82 -82
71% 71%
-17,477%

In millions USD.

Don't miss a Thing! We will send you all news about PureTech Health Plc - ADR directly to your mailbox free of charge.

If you wish, we will send you an e-mail every morning with news on stocks of your portfolios.

PureTech Health Plc - ADR Stock News

Neutral
Business Wire
13 days ago
BOSTON--(BUSINESS WIRE)--PureTech's Deupirfenidone Slowed Lung Function Decline in People w/ IPF, Achieving the Primary & Key Secondary Endpoints in ELEVATE IPF Phase 2b Trial.
Neutral
Business Wire
18 days ago
BOSTON--(BUSINESS WIRE)--PureTech Founded Entity Seaport Therapeutics Presents Additional Data from Phase 1 Study of SPT-300 at ACNP Annual Meeting 2024.
Neutral
Business Wire
20 days ago
BOSTON--(BUSINESS WIRE)--PureTech Presents Data for LYT-200 (anti-galectin-9 monoclonal antibody) for Relapsed/Refractory AML/MDS at the 2024 ASH Annual Meeting.
More PureTech Health Plc - ADR News

Company Profile

PureTech Health Plc is a cross-disciplinary bio-pharmacy company, which engages in the development of treatment programs for obesity, cognitive disorders, baldness, depression, allergy, and autoimmune. It operates through the following segments: Internal, and Affiliates. The Internal segment is advancing a pipeline fuelled by recent discoveries in lymphatics and immune cell trafficking to modulate disease in a tissue-specific manner. The Affiliates segment is comprised of the programmes within PureTech's Affiliates division. The company was founded by Robert S. Langer Jr., Bennett M. Shapiro, and Daphne Zohar on May 8, 2015 and is headquartered in Boston, MA.

Head office United Kingdom
CEO Bharatt Chowrira
Founded 2015
Website puretechhealth.com

Register for Free

StocksGuide is the ultimate tool for easily finding, analyzing and tracking stocks. Learn from successful investors and make informed investment decisions. We empower you to become a confident, independent investor.

The Apple stock at a glance with charts, current key metrics, news and stock analyses.
The Best Dividend Stocks in the Dividend Top Scorer list.
Stock Analyses of the Best Stocks Worldwide.
Start building wealth today